FDA stand on compounding criticized

Share this article:

Public Citizen has written FDA asking it to stop making “misleading” statements about pharmacy compounding that could lead healthcare providers to treat patients with compounded drugs without understanding that they are not as safe as FDA-approved drugs.

The group objects to agency announcements encouraging hospitals and other HCPs to buy medical products from registered compounding or outsourcing facilities. “Because compounded products are fundamentally higher-risk than FDA-approved products,” it said, “[HCPs] should only rely on compounded products after first carefully assessing whether an FDA-approved product is available.” It added that “not all [HCPs] are aware that they should be making this assessment.”

The organization said it was concerned by a December blog post in which FDA commissioner Margaret Hamburg wrote that the agency “will be encouraging [HCPs] and health networks to consider purchasing compounded products from facilities that are registered with FDA.”

Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.